Checkpoint Therapeutics Inc [NASDAQ: CKPT] closed Friday’s session on a high note and looks set to extend those gains in today’s session. That’s because the company’s president and CEO James F. Oliviero will be presenting today at the H.C Wainwright 22nd Annual Global Investment Conference that will start at 3:30 p.m. EDT. Investors will be watching for anything interesting that he will have to say about the company’s ongoing projects.
The company already has several projects that investors will be looking forward to being discussed by the CEO. One of them is Cosibelimab. This is the company’s potentially world best anti-PD-L1 antibody product. Back in August, the company announced that it had made significant progress in the enrolment in the studies. More specifically, the CEO stated that they had a 50% enrollment and that they were expecting full enrolment by the end of the year.
He had also stated that the company was looking forward to a favorable safety profile. At the time, the company announced that if it succeeds on this front, it would mark its entry into the $25 billion PD-(L) 1 market. Investors will be looking forward to his presentation at this event, and see if the company has made any significant progress towards the actualization of this project. Major progress would mean that the company is close to a breakthrough in revenues that could drive up its intrinsic value.
Besides today’s presentation, investors will also be looking forward towards the Lake Street Capital Markets 4th annual best idea growth (BIG4) conference virtual meeting on the 17th of September. Again, they will be looking forward to any big ideas from the company that could see it grow in value in the near-term.
Outside of the upcoming meetings, this stock’s fundamentals are quite good. Back in August, the company reported that its earnings per share had improved significantly compared to a similar period in 2019. More specifically, the company noted that it’s EPS for Q2 of 2020 stood at $0.09 compared to a net loss of $0.15 in Q2 of 2019.
This is indicative of a company that is gaining strength, especially now that the world is emerging from the COVID-19 pandemic. It is an indicator of a company that has strong fundamentals.
Looking at its price action, this stock is in a bullish breakout. If it opens the day above this level, it could close higher, driven by high volumes.
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc is a biopharma company that develops and sells new cancer treatments. It is based in New York, New York.